Differentiation of benign from malignant cervical lymph nodes in patients with head and neck cancer using PET/CT imaging

详细信息    查看全文

• 作者：Seyedmehdi Payabvash ; Kaan Meric ; Zuzan Cayci ; ^{cayci001@umn.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：FDG ; Fludeoxyglucose ; RECIST ; Response Evaluation Criteria In Solid Tumors ; ROC ; receiver-operating characteristics ; SUV-max ; maximum standardized uptake value
• 刊名：Clinical Imaging
• 出版年：2016
• 出版时间：January-February 2016
• 年：2016
• 卷：40
• 期：1
• 页码：101-105
• 全文大小：333 K

文摘

To differentiate malignant from benign cervical lymph nodes in patients with head/neck cancer.

Methods

In this retrospective study, 39 patients with primary head/neck cancer who underwent Positron Emission Tomography (PET)/Computerized Tomography (CT) and image-guided lymph node biopsy were included.

Results

Overall, 23 (59%) patients had biopsy-proven malignant cervical lymphadenopathy. Malignant lymph nodes had higher maximum standardized uptake (SUV-max) value (P< .001) and short-axis diameter (P= .015) compared to benign nodes. An SUV-max of ≥ 2.5 was 100% sensitive, and an SUV-max ≥ 5.5 was 100% specific for malignant lymphadenopathy.

Conclusion

The PET/CT SUV-max value can help with differentiation of malignant cervical lymph nodes in patients with head/neck cancer.